• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Glaukos Stock Could Change Following S&P 400 Inclusion

    Simply Wall St·11/07/2026 10:21:50
    语音播报
    • Glaukos reported third quarter 2026 sales of US$211.03 million and net income of US$2.02 million, raised full year 2026 sales guidance to a range of US$775 million to US$785 million, and received index changes that moved the stock from the S&P 600 into the S&P 400 and its health care sector indices.
    • The combination of a return to quarterly profitability, higher sales guidance and promotion into the S&P 400 has drawn sizeable ETF inflows into Glaukos from funds such as IJH, SPMD and IJK, highlighting how business execution and index status can together influence institutional positioning.
    • Investors can now assess how Glaukos's raised 2026 sales guidance might reshape the existing investment narrative built around iDose TR and Epioxa.

    Scan how Glaukos’ index promotion and guidance reset compares with other potential movers in healthcare by reviewing our curated list of list of solid balance sheet and fundamentals (24 results)

    Glaukos Investment Narrative Recap

    To own Glaukos, you need to believe its interventional glaucoma and corneal franchises, led by iDose TR and Epioxa, can translate clinical interest into consistent procedures and, over time, durable profitability. The third quarter shift to a small profit and higher 2026 sales guidance speak to execution, but the most important near term catalyst is still how quickly payers process and reimburse these procedures.

    The biggest risk remains reimbursement friction and policy decisions that could cap iDose TR revenue and slow Epioxa treatment volumes. The S&P 400 promotion and ETF demand change the shareholder base more than the operating reality, so they do not materially alter that core risk reward equation right now.

    The raised 2026 sales outlook to US$775 million to US$785 million is the announcement that really links to this moment. It ties the index move and ETF flows back to what matters: surgeons using Glaukos products and payers funding that usage at real world volumes and prices across glaucoma and corneal health.

    For catalysts, this guidance reset frames how investors think about the early ramp of iDose TR and Epioxa and the work still needed on coverage, prior authorizations and throughput. Any future update that clarifies Medicare decisions on iDose TR or shows smoother Epioxa reimbursement will likely matter more for the business than further index reshuffling.

    Glaukos' narrative uses analyst assumptions that revenue will reach US$1.2b and earnings will be US$138.6 million by 2029. This implies 25.7% yearly revenue growth and an earnings swing of about US$326.6 million from a loss of US$188.0 million today to the projected profit level.

    Uncover why Glaukos' fair value indicates an 11% potential downside to its current price that leaves little room for error.

    NYSE:GKOS 1-Year Stock Price Chart
    NYSE:GKOS 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most bullish Glaukos analysts lean on a different catalyst. They focus on the higher margin profile and argue that if revenues reached about US$1.7b and earnings US$247.7 million by 2029, the story could look far stronger than consensus assumes. Those projections were set before this earnings beat and index promotion, so you can treat them as one possible, more optimistic path and compare it with other viewpoints before deciding how this new information might shift your own expectations.

    Explore 3 other Glaukos fair value estimates, including one that suggests as much as 63% above the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more Glaukos-like investment ideas?

    Once you have a view on Glaukos, it can help to widen the lens and compare it with other stocks that fit different risk and quality profiles using the Simply Wall St Screener. That way you can see where Glaukos sits in your broader watchlist, rather than treating it in isolation.

    • For investors who want potential upside without sacrificing basic financial strength, review our curated 19 high quality undiscovered gems that combine quality fundamentals with lower profile coverage.
    • If capital preservation and balance sheet resilience matter most to you, start with a focused 29 resilient stocks with low risk scores that filters for companies with sturdier financial risk scores.
    • Income focused investors who care about cash returns may prefer a targeted 8 dividend fortresses that highlights stocks offering higher yields backed by underlying fundamentals.